Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.68 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 9/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 9/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | GLA | P06280 | 5/20 | 0.53 |
| ▸ | GFER | P55789 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028984 | 0.86 | KDM4E (0.50) | MAPTKDM4ESCN10AKCNH2ALDH1A1 | |
| SCHEMBL521212 | 0.82 | MAPT (0.97) | MAPTKDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL3269719 | 0.80 | ALDH1A1 (0.58) | MAPTKDM4ESCN10AKCNH2ALDH1A1 | |
| SCHEMBL846652 | 0.80 | SCN10A (0.78) | SCN10AKCNH2ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL16599615 | 0.79 | MAPT (0.73) | MAPTKDM4EALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL18659837 | 0.79 | ALDH1A1 (0.56) | MAPTKDM4ESCN10AKCNH2ALDH1A1 | |
| SCHEMBL10248233 | 0.79 | ALDH1A1 (0.61) | MAPTKDM4ESCN10AKCNH2ALDH1A1 | |
| SCHEMBL10220066 | 0.79 | ALDH1A1 (0.56) | MAPTKDM4ESCN10AKCNH2ALDH1A1 | |
| SCHEMBL846648 | 0.77 | KDM4E (0.56) | MAPTKDM4ESCN10AKCNH2ALDH1A1 | |
| SCHEMBL2708178 | 0.76 | ALDH1A1 (0.54) | MAPTKDM4ESCN10AKCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20030181730-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-25 | — | — | US | disclosed |
| US-20030022927-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6495583-B1 | DRUG FOR TREATING AN ALPHA-2 ADRENERGIC RECEPTOR ASSOCIATED DISORDER, NASAL CONGENSTION AND ALLEVIATING PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-12-17 | — | — | US | disclosed |
| US-6436982-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-20 | — | — | US | disclosed |
| US-20020072536-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6316637-B1 | SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | MAPT 4094/4885KDM4E 1828/4885SCN10A 444/4885 |
| US-20020072536-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | MAPT 4095/4885KDM4E 1775/4885SCN10A 440/4885 |
| US-20030022927-A1 | Novel benzimidazole derivatives | OPRL1, OPRD1, OPRM1 | MAPT 4207/4885KDM4E 2083/4885SCN10A 518/4885 |
| US-20030181730-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | MAPT 4094/4885KDM4E 1828/4885SCN10A 444/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | MAPT 3109/4885KDM4E 192/4885SCN10A 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.